Delivered as Hybrid Event from 15-19 November 2021
Live In-Person Conference Delivered 15-17 NovemberSheraton Airport Brussels, BelgiumMark Schlegel, PhDPrincipal Scientist, RNAi Discovery at Alnylam Pharmaceuticals
Profile
Mark joined Alnylam Pharmaceuticals in 2014 where he is currently a Principal Scientist in the RNAi Discovery group. At Alnylam, Mark leads the high throughput RNA synthesis team, the siRNA lead discovery team, and several platform development efforts. Prior to joining Alnylam, Mark held the position of Head of Automation at GlycoUniverse GmbH & CO KGaA. Mark received his undergraduate degree in chemistry from Moravian College, a PhD in Chemical Biology from the University of Pennsylvania, and was a postdoctoral fellow at the Max Planck Institute of Colloids and Interfaces.
Agenda Sessions
Improved Specificity of Conjugate siRNAs Through Chemical Modification
On DemandView SessionMedicinal Chemistry of RNA Therapeutics
15:45View Session